Marking a significant advance in infant safety, the U.S. Food and Drug Administration (FDA) has given De Novo approval to Happiest Baby’s SNOO Smart Sleeper. This is the first time the FDA has given De Novo approval to a product designed to keep sleeping babies safely positioned on the back. Babies who are positioned to sleep on the back are at a lower risk of SIDS. Amy Schumer, Tia Mowry, Ashton Kutcher, Gigi Hadid, Serena Williams, and Kate Hudson are just a few who have used and praised the SNOO Smart Sleeper. Michelle speaks with Dr. Harvey Karp about how to calm your baby and the great benefits of the SNOO.

Due to severe food allergies, Hero Bread Founder Cole Glass has an extremely limited diet. He can’t eat raw fruits, vegetables or nuts, which means he’s limited to protein, fat and carbs. Glass was worried about the health impacts of all the carbohydrate-dense foods he was eating and started searching for a low net carb bread. The problem was, most of the alternative flour products were made from foods he couldn’t eat. So, he decided to bake. Without a culinary background, it took two years of experimentation and 73,000 muffins, but practice paid off and he found the perfect recipe. His bread has zero grams of sugar, 12 grams of protein and only 1 net carb per serving.That journey led him to big-name investors, expansion into quick-service and his latest Series B fundraise (bringing total funding to date to $47.5 million). Hero Bread is also expanding to 2,300 grocery retail stores nationwide.

Milan Kordestani, an expert for “Gen Next” (Millennials, Gen Z, and Gen Alpha). He is an entrepreneur, writer, and founder of several companies, who is redefining the meaning of success in business. With a focus on building sustainable businesses that drive positive social change at scale, Milan is a three-time founder who wants to encourage solutions beyond his companies through storytelling and narration of civil discourse. Milan is also the author of “I’m Just Saying: A Guide to Maintaining Civil Discourse in an Increasingly Divided World,” (April, 2023 HCI) a straightforward look at the history and art of maintaining courteous communication in an increasingly divided world. In this book, he uses contemporary case studies and personal experience to teach readers how to have constructive conversations by engaging in civil discourse, and provides practical advice and strategies for respect in a divided world.

Dr. Mothaffar F. Rimawi is a Professor of Medicine, co-Leader of the Breast Cancer Research Program, and Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine. Metastatic breast cancer (mBC) is the most serious form of the disease and occurs when the cancer has spread beyond the breast to other parts of the body, such as the brain, bones, or liver.1 mBC has no cure and takes a life in the United States approximately every 12 minutes, creating an urgent need for treatment proven to extend life while maintaining quality of life.

Despite remaining gaps, there have been important advancements in treatment for patients with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) mBC. For example, KISQALI® (ribociclib), a prescription medicine indicated for HR+/HER2- mBC in combination with endocrine therapy (ET), has consistently demonstrated across three phase III clinical trials a significant benefit in overall survival (OS) – the length of time that patients diagnosed with mBC continue to be alive – while preserving or improving quality of life.